Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.

< BACK TO ARCHIVE


Papers: 6 Feb 2021 - 12 Feb 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Feb 10


Clin Pharmacokinet


http://www.ncbi.nlm.nih.gov/pubmed/33565026?dopt=Abstract

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.

Authors

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine.
Tsai M, Nery E S M, Kerr L, Khanna R, Komori M, Dennehy EB, Wilbraham D, Winner P
Clin Pharmacokinet. 2021 Feb 10.
PMID: 33565026.

Abstract

Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to < 18 years.
Read This Paper